Loading clinical trials...

Study Evaluating the Effect of Sirolimus on Non-Melanoma Skin Cancer in Kidney Transplant Recipients | Clinical Trials | Clareo Health

COMPLETEDPHASE4

Study Evaluating the Effect of Sirolimus on Non-Melanoma Skin Cancer in Kidney Transplant Recipients

A Randomized, Open-Label Study to Compare the Rate of New Non-Melanoma Skin Cancer in Maintenance Renal Allograft Recipients Converted to a Sirolimus-based Regimen Versus Continuation of a Calcineurin Inhibitor-based Regimen

NCT00129961•Wyeth is now a wholly owned subsidiary of Pfizer

View on ClinicalTrials.gov

Summary

The purpose of this study is to determine the effect of sirolimus on the prevention of new non-melanoma skin cancer (NMSC) in kidney transplant recipients.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Kidney transplant at least 1 year prior
•Subjects with a functioning renal allograft with calculated glomerular filtration rate (GFR) ≥40mL/min (Nankivell method) and proteinuria ≤500mg/day.
•Stable on cyclosporine or tacrolimus-based multi-drug immunosuppressive regimen
•History of NMSC within last 3 years

Exclusion Criteria

•History of other cancer within last 3 years
•NMSC with metastatic disease or more than 20 NMSC lesions in last 12 months
•Multiple organ transplant

Locations (23)

San Diego, California, United States

San Francisco, California, United States

Gainesville, Florida, United States

Atlanta, Georgia, United States

Chicago, Illinois, United States

Durham, North Carolina, United States

Cincinnati, Ohio, United States

Portland, Oregon, United States

Philadelphia, Pennsylvania, United States

Charleston, South Carolina, United States

Key Dates

Start Date

August 1, 2005

Primary Completion Date

January 1, 2009

Completion Date

January 1, 2009

Last Updated

April 11, 2012

Enrollment

ACTUAL participants

Conditions

Skin NeoplasmsKidney Transplantation

Interventions

sirolimus

DRUG

cyclosporine or tacrolimus

DRUG

Electrochemotherapy-Induced Changes in Tumor Microenvironment in Cutaneous Melanoma

NCT07404605

MELANOMASKIN NEOPLASMS

View study

RECRUITINGNA

Parathyroidectomy After Kidney Transplantation

NCT07415421

HyperparathyroidismKidney Transplantation Recipients

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 11, 2012Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Study Evaluating the Effect of Sirolimus on Non-Melanoma Skin Cancer in Kidney Transplant Recipients

Inclusion Criteria

Exclusion Criteria

Electrochemotherapy-Induced Changes in Tumor Microenvironment in Cutaneous Melanoma

Parathyroidectomy After Kidney Transplantation

Strategic Help With Immunoglobulin to Enhance Protect Against Late Disease (CMV)

Is Valacyclovir Non-inferior to Valganciclovir as CMV and EBV Prophylaxis in Kidney Transplant Recipients? A Single-Center Prospective Randomized Pilot Study

Study to Evaluate the Safety and Efficacy of the GGTA1 KO Thymokidney in Patients With ESRD

Tolerance Through Mixed Chimerism (Sip-Tego)